Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM

Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM

Potassium para-aminobenzoate (POTABA) is used to treat Peyronie’s disease by decreasing fibrosis and plaque size progression. Among potential side effects, drug-induced liver injury (DILI) attributed to POTABA administration has been reported in a few cases and inferred to immune hypersensitivity. I...

Full description

Bibliographic Details
Main Authors: Marlene Plüß, Désirée Tampe, Harald Schwörer, Sebastian Christopher Benjamin Bremer, Björn Tampe
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
hepatotoxicity
acute hepatitis
drug-induced liver injury
Roussel Uclaf causality assessment method
updated RUCAM
potassium para-aminobenzoate
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.966910/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.966910/full

Similar Items